Status:

COMPLETED

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

Lead Sponsor:

UCB Pharma SA

Conditions:

Crohn's Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation...

Eligibility Criteria

Inclusion

  • Participation in either of the CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] clinical studies in which the subject completed the Week 2 assessment in CDP870-031 \[NCT00152490\] or the Week 6 randomization in CDP870-032 \[NCT00152425\] but whose Crohn's Disease was significantly worse as determined by the investigator and whose Clinical Disease Activity Index (CDAI) score at entry to this study is either (subjects may have received active or placebo treatment):
  • At least 70 points higher then Baseline (Week 0 CDP870-031 \[NCT00152490\]; Week 6 CDP870 032 \[NCT00152425\] responders) OR
  • Higher than Baseline (Week 0 CDP870-031 \[NCT00152490\]; Week 6 CDP870-032 \[NCT00152425\] responders) with an absolute score of at least 350 points
  • Subjects must be able to understand the information provided to them and give written informed consent

Exclusion

  • Any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\]), although the upper limit of 450 in the CDAI score is not applicable. In addition the criterion that excludes previous participation in a clinical trial of Certolizumab Pegol does not apply

Key Trial Info

Start Date :

February 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

310 Patients enrolled

Trial Details

Trial ID

NCT00160706

Start Date

February 1 2004

End Date

May 1 2012

Last Update

August 7 2018

Active Locations (141)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 36 (141 locations)

1

45102

Birmingham, Alabama, United States

2

45028

Huntsville, Alabama, United States

3

45044

Little Rock, Arkansas, United States

4

45095

Orange, California, United States